Holden, MA 01520-1838, USPharmaceuticalswww.sevonutraceuticals.com/
Sevo Nutraceuticals is a rapidly growing company that was launched in June 2012 with a vision to become a market leader in highly efficacious, science-backed nutraceuticals that improve people's lives. In August 2012, the company launched its flagship product, PERCEPTIV®. PERCEPTIV® is a patented formula based on research that was funded by UMASS Lowell, the Alzheimer's Association, the National Institute on Aging, and the National Science Foundation. UMASS Lowell licensed the intellectual property including patents, a trademark and know-how to Sevo in June 2012. PERCEPTIV® is based on seven independent, national clinical studies performed by UMASS Lowell professor Dr. Thomas Shea and his team, in which the supplement improved cognitive performance not only for healthy adults but also for those with cognitive impairment.* PERCEPTIV® is a patented combination of S-adenosyl methionine, Acetyl-L-Carnitine, N-acetyl Cysteine, Folic acid, B12 & vitamin E. It is our patented combination that is proven strongly effective in multiple clinical studies.* PERCEPTIV® protects against the normal cognitive decline associated with aging and is clinically proven to enhance mental clarity, help improve memory, and help restore a healthy mood.*Bernie Prusaczyk, Chief Executive Officer, is an experienced entrepreneur and business executive with over 25 years' experience in sales, marketing and business development. He has been at the core of several start-ups from pre-revenue to rapid revenue growth and successful exits. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Viewable by EquityNet investors only
Is this company privately-held or publicly-traded?
PERCEPTIV® is a cognitive nutraceutical that increases production of a key neurotransmitter – acetylcholine, which is responsible for transfer of messages between synapses critical to thinking and memory.*Acetylcholine normally breaks down rapidly so the brain can quickly move on to new thoughts. But if it breaks down too fast, the message isn't transmitted. During normal aging, acetylcholine production declines. Acetylcholine is broken down before it can "complete" the thought (or there is not enough of it to begin with). PERCEPTIV® protects against the normal cognitive decline associated with aging and is clinically proven to enhance mental clarity, help improve memory, and help restore a healthy mood.**These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Bernie Prusaczyk, Chief Executive Officer, is an experienced entrepreneur and business executive with over 25 years' experience in sales, marketing and business development. He has been at the core of several start-ups from pre-revenue to rapid revenue growth and successful exits. Of note in the start-up arena, Mr. Prusaczyk's sales leadership helped grow a division of Agfa (now Monotype Imaging) from less than $2MM to over $30MM during his tenure. As VP Worldwide Business Development and Channels of NuGenesis Technologies, Mr. Prusaczyk helped grow the company from $0 to $25MM and exited with the successful sale of the company to Waters Corporation.
PERCEPTIV® is the result of 20 years of research, led by Dr. Thomas Shea, Director of the Center for Cellular Neurobiology & Neurodegeneration Research at the University of Massachusetts-Lowell. Previous to UMASS, Dr. Shea studied at Harvard Medical School focusing on the development of the nervous system.Dr. Shea conducted 7 independent clinical studies on the PERCEPTIV® formula. 6 of the studies are published in peer-reviewed scientific journals, including a phase II study funded by the Alzheimer's Association, and an additional study is pending publication.Over the past 20 years, Dr. Shea has led to the publication of more than 60 scientific reports and to the development and patenting of the PERCEPTIV® formulation. He has also contributed to over 300 additional healthcare publications surrounding brain function and health.
To find out if this company and others are accepting funding, Sign up as Investor.
Funding GoalSign up as Investor
Funding Raised So FarSign up as Investor
Funding CommitmentsSign up as Investor
Funding RemainingSign up as Investor
Funding TypeSign up as Investor
Pre-Money Valuation Sign up as Investor
Investor Ownership Sign up as Investor
Interest / Dividend Sign up as Investor
Previous Funding Sign up as Investor
Showing your General Funding information publicly may constitute general solicitation. General solicitation is a new commonly-used way for companies to raise funding. To learn about general solicitation, consult your legal counsel. If you uncheck this box, your General Funding information will be viewable to only EquityNet investors.
Your EquityNet business plan is only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab. Investors prefer an EquityNet business plan. Entering a plan is highly educational and improves your appeal to investors.
Document file names will be viewable by EquityNet investors and business supporters only. Actual documents are only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab.
Users who follow all these tips increase their fundraising odds substantially.
Your Public Profile Page:
Would you like to share your public profile page with your email contacts?
"EquityNet is the only patented crowdfunding platform in the world"
"Where to find funding for your Business"
"EquityNet is addressing 90 percent of the business community that was previously starved for capital"